GSK Advances Oligonucleotide Research with Elsie Biotechnologies Platform License
February 14, 2024
GlaxoSmithKline (GSK) has solidified its commitment to oligonucleotide therapeutics by securing a nonexclusive license to Elsie Biotechnologies’ discovery platform following a successful research collaboration. This agreement, announced on Valentine’s Day, allows GSK to integrate Elsie’s technology and P(V) chemistry into its drug discovery efforts. While financial details were not disclosed, Elsie stands to gain from license payments and potential development and commercial milestones.
Elsie’s platform specializes in high-throughput processes that optimize the activity and delivery of oligonucleotide therapies while minimizing toxicity. GSK, maintaining a solid presence in the oligonucleotide space, previously invested in Wave Life Sciences for RNA-targeting therapies and is advancing bepirovirsen, a potential hepatitis B cure in phase 3 trials, among other projects. Despite recent leadership changes, GSK’s latest move reaffirms its dedication to oligonucleotide drug development.
To read more, click here.
[Source: Fierce Biotech, February 14th, 2024]
